https://scholars.lib.ntu.edu.tw/handle/123456789/468679
標題: | Intratumoral injection of thermogelling and sustained-release carboplatin-loaded hydrogel simplifies the administration and remains the synergistic effect with radiotherapy for mice gliomas | 作者: | Liang H.-K.T. Lai X.-S. Wei M.-F. Lu S.-H. Wen W.-F. SUNG-HSIN KUO Chen C.-M. WEN-YIH TSENG CHUNG-MING CHEN FENG-HUEI LIN HSIANG-KUANG LIANG |
公開日期: | 2018 | 出版社: | Elsevier Ltd | 卷: | 151 | 起(迄)頁: | 38-52 | 來源出版物: | Biomaterials | 摘要: | Background Carboplatin, an antineoplastic agent, binds DNA and enhances radiotherapy (RT) effects. Carboplatin-loaded hydrogel (oxidized hyaluronic acid/adipic acid dihydrazide) enables the sustained drug release and facilitates the synergistic effect with RT. Purpose We investigated the effectiveness and convenience of hydrogel carboplatin combined with RT for mice glioma. Materials and methods Mouse glioma cells (ALTS1C1) were subcutaneously implanted in the right thigh of C57BL/6 mice on Day 0. The mice were categorized by treatments: sham, hydrogel, hydrogel carboplatin, aqueous carboplatin, RT, hydrogel carboplatin/RT, and aqueous carboplatin/RT. Hydrogel carboplatin (300 μg single dose on Day 7) or aqueous carboplatin (100 μg daily dose on Days 7, 8, and 9) was administered via intratumoral injection. RT was delivered a daily dose of 10 Gy on Days 8 and 9. Results For mice administered hydrogel carboplatin/RT versus those administered aqueous carboplatin/RT, the 24-day tumor growth control rate and 104-day recurrence-free survival rate were 100% and 50% versus 100% and 66.7% (p = 0.648), respectively. However, mice receiving other treatments showed tumor progression by Day 24 and died within 40 days of tumor cell implantation. Conclusions Hydrogel carboplatin simplified intratumoral drug delivery and remained the synergistic effects with RT, which is potential for clinical applications. ? 2017 Elsevier Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85032023911&doi=10.1016%2fj.biomaterials.2017.10.015&partnerID=40&md5=73daae0876b4f5b16443b37b12569a24 https://scholars.lib.ntu.edu.tw/handle/123456789/468679 |
ISSN: | 0142-9612 | DOI: | 10.1016/j.biomaterials.2017.10.015 | SDG/關鍵字: | Drug products; Hyaluronic acid; Hydrogels; Mammals; Radiotherapy; Targeted drug delivery; Tumors; Carboplatin; Concurrent chemoradiotherapy; Intratumoral injection; Malignant glioma; Thermogelling; Controlled drug delivery; carboplatin; antineoplastic agent; carboplatin; drug carrier; animal cell; animal experiment; animal model; animal tissue; Article; cancer inhibition; cancer survival; cell death; cell proliferation; cell viability; controlled study; degradation; drug efficacy; drug megadose; feasibility study; glioma; hydrogel; IC50; low drug dose; male; mouse; nonhuman; overall survival; priority journal; recurrence free survival; single drug dose; survival rate; survival time; sustained drug release; tumor growth; tumor volume; weight reduction; 3T3 cell line; animal; brain tumor; C57BL mouse; cell survival; chemistry; delayed release formulation; drug release; glioma; human; hydrogel; intralesional drug administration; materials testing; multimodality cancer therapy; procedures; tissue distribution; tumor cell line; 3T3 Cells; Animals; Antineoplastic Agents; Brain Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Glioma; Humans; Hydrogels; Injections, Intralesional; Materials Testing; Mice; Mice, Inbred C57BL; Tissue Distribution |
顯示於: | 醫療器材與醫學影像研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。